The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast. [electronic resource]
Producer: 20180620Description: 1009-1011 p. digitalISSN:- 1365-2559
- Adult
- Aged
- Antineoplastic Agents, Immunological -- therapeutic use
- Breast Neoplasms -- drug therapy
- Carcinoma, Intraductal, Noninfiltrating -- drug therapy
- Chemotherapy, Adjuvant -- methods
- Female
- Humans
- Middle Aged
- Neoadjuvant Therapy -- methods
- Receptor, ErbB-2 -- immunology
- Retrospective Studies
- Trastuzumab -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Letter
There are no comments on this title.
Log in to your account to post a comment.